- QIAGEN and Lilly collaborate to develop the first QIAstat-Dx IVD panel for APOE genotyping to aid Alzheimer’s diagnosis.
- This panel, using QIAGEN’s multiplex real-time PCR technology, will be the first commercially available IVD kit for neurodegenerative applications.
September 04 2024 20:10:17 UTC– QIAGEN and Lilly collaborate on developing a QIAstat-Dx IVD panel to identify patients at risk for Alzheimer’s disease, specifically focusing on APOE genotypes.
This specific panel is designed to test for different versions (genotypes) of the APOE gene, which is important in determining a person’s risk for Alzheimer’s disease. Essentially, it’s a medical test that will help doctors quickly identify whether a patient has certain genetic markers that are associated with a higher risk of developing Alzheimer’s.
The panel will be the first commercially available IVD for APOE genotyping, integrated with QIAGEN’s multiplex testing platform for faster, reliable results in about an hour.
This collaboration aims to provide valuable insights for treatment considerations in Alzheimer’s patients.